A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma
Sponsor: CStone Pharmaceuticals
A PHASE3 clinical study on Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, this trial is completed. The trial is conducted by CStone Pharmaceuticals and has accumulated 14 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
Mar 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Feb 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2019 — Apr 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .